Yes, the FDA indicated to Cytodyn that the HIV receptor occupancy tests were unacceptable. Therefore, the tests need to be re-run, which is in-process, but very time-consuming.

CytoDyn asked the FDA if the BLA can be re-submitted without those test results, to accelerate the BLA Acceptance/PDUFA Date process. The intent would be that CytoDyn would submit the receptor occupancy tests afterward, in a staggered manner, as soon as they are completed.

So, I want to learn the FDA's disposition on this topic, as a rejection would clearly add significant time to the BLA re-submission date.